Perceptive Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Perceptive Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-100,000	Closed	-$183K	–	158
2018 Q1	$183K	Buy	+100,000	New	+$211K	0.01%	132
2017 Q2	–	Sell	-978,100	Closed	-$4.56M	–	184
2017 Q1	$4.56M	Buy	978,100 +487,800	+99%	+$2.83M	0.26%	64
2016 Q4	$2.99M	Buy	490,300 +401,173	+450%	+$2.1M	0.21%	72
2016 Q3	$491K	Buy	+89,127	New	+$417K	0.03%	131
2015 Q4	–	Sell	-226,000	Closed	-$1.2M	–	187
2015 Q3	$1.2M	Buy	+226,000	New	+$1.75M	0.1%	94

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Perceptive Advisors's SGYP Position: Q2 2018 in Review

Perceptive Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2018, closing a stake of 100,000 shares — an estimated $183K sold.

Perceptive Advisors first reported a position in SGYP in Q3 2015 and held it in 5 quarters. The position peaked at $4.56M in Q1 2017. 136 funds tracked by Wall St. Rank hold SGYP as of Q2 2018.

Perceptive Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2018 after selling out during the quarter.
Perceptive Advisors sold 100,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2018, an estimated $183K.
Perceptive Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q3 2015 and held it in 5 quarters.
Perceptive Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $4.56M in Q1 2017.
136 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.